

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Complete if Known

Application Number

10/561,829

Filing Date

December 21, 2005

First Named Inventor

Shaharvar Khan

Group Art Unit

1633

Examiner Name _____

Qian Janice L

Attorney Docket Number

GNC 0001

Short

1

1

Attorney Docket Number

GNC 0001

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner's
Signature

Date	
Considered	

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

45095322v1

635C 9007

0603 4943000 1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./



Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it carries a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/561,829
		Filing Date	December 21, 2005
		First Named Inventor	Shaharyar Khan
		Group Art Unit	1633
		Examiner Name	Qian Janice Li
Sheet 2 of 2	Attorney Docket Number	GNC 0001	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published	T ²
		OPALANSKA, et al., "Nucleic-acid therapeutics: basic principles and recent applications", <i>Nat. Rev. Drug. Dis.</i> , 1:503-514 (2002).	
		RUSSELL, "Replicating vectors for gene therapy of cancer: risks, limitations and prospects", <i>Eur. J. Cancer</i> , 30A(8):1165-1171 (1994).	
		SANDIG, et al., "Direct gene transfer of HMG1 based DNA-protein complexes", <i>J. Mol. Med.</i> , 73:B10 (1995) (Abstract).	
		SCHRANK, "Functional expression of the yeast Mn-superoxide dismutase gene in Escherichia coli requires deletion of the signal peptide sequence", <i>Gene</i> , 73(1):121-30 (1988).	

Examiner's Signature	/Qian Janice Li/ (10/02/2009)	Date Considered	
----------------------	-------------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.